Photo by atikahakhtar from unsplash
Sex, n (%) Male 29/41 (70.7) Female 12/41 (29.3) Mean age, y 6 SD 45.0 6 11.0 No. of previously failed biologic therapies, mean 6 SD PASI 75 responders at… Click to show full abstract
Sex, n (%) Male 29/41 (70.7) Female 12/41 (29.3) Mean age, y 6 SD 45.0 6 11.0 No. of previously failed biologic therapies, mean 6 SD PASI 75 responders at wk 52 2.2 6 1.4 NonePASI 75 responders at wk 52 2.5 6 1.1 Efficacy Wk 52 outcomes, n (%) $PASI 75 or PGA 0 or 1 28/41 (68.3) \PASI 75, PGA[1, or discontinued 13/41 (31.7) Discontinuation before wk 52, n (%) 11/41 (26.8) Lack of efficacy 10 (24.4) Intolerance 1 (2.4) Mean treatment duration, wk 6 SD 40.0 6 7.1 Safety No. of patients with $ 1 AE, n (%) 7/41 (17.1) Reported AEs, n (%) Diarrhea 2 (4.9) Nasopharyngitis 1 (2.4) Bronchitis 1 (2.4) Cutaneous candidiasis 1 (2.4) Superficial skin bacterial infection 1 (2.4) Fever 1 (2.4) Abdominal pain 1 (2.4) Vomiting 1 (2.4) Bloody stool 1 (2.4) Neutropenia 1 (2.4)
Journal Title: Journal of the American Academy of Dermatology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!